UA15776U - Антибиотик пролонгированного действия липофлок - Google Patents
Антибиотик пролонгированного действия липофлок Download PDFInfo
- Publication number
- UA15776U UA15776U UAU200600555U UAU200600555U UA15776U UA 15776 U UA15776 U UA 15776U UA U200600555 U UAU200600555 U UA U200600555U UA U200600555 U UAU200600555 U UA U200600555U UA 15776 U UA15776 U UA 15776U
- Authority
- UA
- Ukraine
- Prior art keywords
- drug
- lecithin
- ofloxacin
- tween
- animals
- Prior art date
Links
- 230000003115 biocidal effect Effects 0.000 title claims abstract 4
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 claims abstract description 10
- 229960001699 ofloxacin Drugs 0.000 claims abstract description 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 9
- 241001465754 Metazoa Species 0.000 claims abstract description 9
- 229940067606 lecithin Drugs 0.000 claims abstract description 9
- 235000010445 lecithin Nutrition 0.000 claims abstract description 9
- 239000000787 lecithin Substances 0.000 claims abstract description 9
- 229920000136 polysorbate Polymers 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 26
- 239000000839 emulsion Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000008215 water for injection Substances 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 2
- 238000012876 topography Methods 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 230000002035 prolonged effect Effects 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000000845 anti-microbial effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 1
- 108010054814 DNA Gyrase Proteins 0.000 description 1
- 241001430197 Mollicutes Species 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009476 short term action Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Антибиотик для лечения животных при заболеваниях воспалительного характера содержит офлоксацин, а также тривитамин (А, Д3, Е), лецитин и твин.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAU200600555U UA15776U (ru) | 2006-01-20 | 2006-01-20 | Антибиотик пролонгированного действия липофлок |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAU200600555U UA15776U (ru) | 2006-01-20 | 2006-01-20 | Антибиотик пролонгированного действия липофлок |
Publications (1)
Publication Number | Publication Date |
---|---|
UA15776U true UA15776U (ru) | 2006-07-17 |
Family
ID=37503358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAU200600555U UA15776U (ru) | 2006-01-20 | 2006-01-20 | Антибиотик пролонгированного действия липофлок |
Country Status (1)
Country | Link |
---|---|
UA (1) | UA15776U (ru) |
-
2006
- 2006-01-20 UA UAU200600555U patent/UA15776U/ru unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Teixeira et al. | Comparison of intrarectal ozone, ozone administered in acupoints and meloxicam for postoperative analgesia in bitches undergoing ovariohysterectomy | |
CN102697784B (zh) | 一种兽用恩诺沙星注射液及其制备方法 | |
ES2826825T3 (es) | Composiciones y métodos para el tratamiento de la psoriasis | |
US10300012B2 (en) | Topical composition comprising extracts of boldo and of meadowsweet, intended for an animal, and uses thereof | |
MX2010014446A (es) | Nuevas posibilidades de lucha contra la giardiasis. | |
KR20220154142A (ko) | 생물막 형성 방해 및 생물막 관련 질환 치료용 조성물 | |
US20140377357A1 (en) | Poloxamer Based Inhalation Composition | |
RU2367433C1 (ru) | Препарат для лечения мастита у коров в период лактации | |
Talokar et al. | Clinical evaluation of cow-urine extract special reference to Arsha (Hemmorrhoids) | |
UA15776U (ru) | Антибиотик пролонгированного действия липофлок | |
JP2007506645A (ja) | 抗腫瘍および抗転移のための製剤の製造におけるn−アセチル−d−グルコサミンの使用 | |
CN1199645C (zh) | N-乙酰-d-氨基葡萄糖在制备治疗泌尿生殖道感染药物中的应用 | |
WO1993000892A1 (en) | Pharmaceutical preparation | |
RU2218167C2 (ru) | Способ получения композиционного средства - мази "свф" | |
RU2799015C1 (ru) | Способ местного лечения болезней копытец у крупного рогатого скота на основе комбинации действующих компонентов | |
UA39443U (ru) | Нанопрепарат широкого спектра лечебного действия для лечения болезней сельскохозяйственных животных и птицы | |
BR112023018979A2 (pt) | Formulações de tasipimidina e uso das mesmas | |
UA19309U (en) | Interflock, composition for increasing antioxidant status and immune potential in cattle | |
RU2419434C1 (ru) | Крем для лечения заболеваний кожи у мелких домашних животных | |
RU2105548C1 (ru) | Препарат "диарин" для лечения и профилактики желудочно-кишечных болезней молодняка животных | |
RU2024119390A (ru) | Применение аминопиразольных соединений | |
RU2173143C2 (ru) | Способ пролонгированной химиопрофилактики пироплазмидозов овец и коз | |
UA119202C2 (uk) | Антимікробний препарат пролонгованої дії мінімаст | |
CN103933545B (zh) | 治疗真菌感染的药物及其制备方法 | |
RU2428194C1 (ru) | Средство для лечения желудочно-кишечных заболеваний животных |